What Is the Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy?

  • F. Cecchi
  • I. Olivotto
Conference paper


Atrial fibrillation (AF) is the most common sustained arrhythmia in patients with hypertrophic cardiomyopathy (HCM), with a reported prevalence ranging from 10% to 28% [1–13]. In a recent study involving 480 patients with HCM followed up at two institutions for over 9 years, AF was documented in 22% of patients, with an incidence of 2% new cases per year [4]. Comparison with the general population shows that the likelihood of developing AF is 4–6 times in HCM patients at any given age. AF became progressively more common with age in HCM patients, and particularly after the age of 60 years; the mean age at onset of the arrhythmia was 54 years for paroxysmal AF and 57 years for chronic AF [4]. However, over one–third of patients with AF developed their arrhythmia before the age of 50 years, and these patients were at greater risk of clinical deterioration and HCM-related death than were patients with AF onset later in life [4]. Finally, postoperative AF occurred following surgical septal myectomy in approximately 30% of patients in one series [13].


Atrial Fibrillation Hypertrophic Cardiomyopathy Atrial Fibrillation Patient Postoperative Atrial Fibrillation Trophic Cardiomyopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Maron BJ (1997) Hypertrophic cardiomyopathy. Lancet 350:127–133PubMedCrossRefGoogle Scholar
  2. 2.
    Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hyper-trophic cardiomyopathy. N Engl J Med 336:775–785PubMedCrossRefGoogle Scholar
  3. 3.
    Maron MS, Olivotto I, Betocchi S et al (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295–303PubMedCrossRefGoogle Scholar
  4. 4.
    Olivotto I, Cecchi F, Casey SA et al (2001) Impact of atrial fibrillation on the clinical course of hypertrophie cardiomyopathy. Circulation 104:2517–2524PubMedCrossRefGoogle Scholar
  5. 5.
    Cecchi F, Olivotto I, Montereggi A et al (1995) Hypertrophie cardiomyopathy in Tuscany: clinical course and outcome in an unselected population. J Am Coll Cardiol 26:1529–1536PubMedCrossRefGoogle Scholar
  6. 6.
    Maron BJ, Casey SA, Poliac L et al (1999) Clinical course of hypertrophie cardiomyopathy in a Regional United States Cohort. JAMA 281:650–655PubMedCrossRefGoogle Scholar
  7. 7.
    Cecchi F, Montereggi A, Olivotto I et al (1997) Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal-averaged P-wave. Heart 78:44–49PubMedGoogle Scholar
  8. 8.
    McKenna WJ (1983) Arrhythmia and prognosis in hypertrophic cardiomyopathy. Eur Heart J 4[SupplF]:225–234PubMedCrossRefGoogle Scholar
  9. 9.
    Savage DD, Seides SF, Maron BJ et al (1979) Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 59:866–875PubMedCrossRefGoogle Scholar
  10. 10.
    McKenna WJ, England D, Doi YL et al (1981) Arrhythmia in hypertrophic cardiomyopathy. I. Influence on prognosis Br Heart J 46:168–172CrossRefGoogle Scholar
  11. 11.
    Glancy DL, O’Brien KP, Gold HK, Epstein SE (1970) Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. Br Heart J 32:652–659PubMedCrossRefGoogle Scholar
  12. 12.
    Robinson KC, Frenneaux MP, Stockins B et al (1990) Atrial fibrillation in hyper-trophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 15:1279–1285PubMedCrossRefGoogle Scholar
  13. 13.
    Ommen SR, Thomson HL, Nishimura RA et al (2002) Clinical predictors and consequences of atrial fibrillation after surgical myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 89:242–244PubMedCrossRefGoogle Scholar
  14. 14.
    Benjamin EJ, Wolf PA, D’Agostino RB et al (1998) Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 98:946–952PubMedCrossRefGoogle Scholar
  15. 15.
    Maron BJ, Olivotto I, Spirito P et al (2000) Epidemiology of hypertrophic cardiomyo-pathy-related death: revisited in a large non-referral based patient population. Circulation 102:858–864PubMedCrossRefGoogle Scholar
  16. 16.
    Cecchi F, Maron BJ, Epstein SE (1989) Long-term outcome of patients with hyper-trophic cardiomyopahy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 13:1283–1288PubMedCrossRefGoogle Scholar
  17. 17.
    Stafford WJ, Trohman RG, Bilsker M et al (1986) Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 7:701–704PubMedCrossRefGoogle Scholar
  18. 18.
    Lopez Gil M, Arribas F, Cosio FG (2000) Ventricular fibrillation induced by rapid atrial rates in patients with hypertrophic cardiomyopathy. Europace 2:327–332CrossRefGoogle Scholar
  19. 19.
    Furlan AJ, Craciun AR, Raju NR, Hart N (1984) Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis. Stroke 15:282–284PubMedCrossRefGoogle Scholar
  20. 20.
    Di Pasquale G, Andreoli A, Lusa AM et al (1990) Cerebral embolie risk in hyper-trophic cardiomyopathy. In: Baroldi G, Camerini F, Goodwin J (eds) Advances in Cardiomyopathies. Springer, Milan, pp. 91–96Google Scholar
  21. 21.
    Maron BJ, Olivotto I, Bellone P et al (2002) Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 39:301–307PubMedCrossRefGoogle Scholar
  22. 22.
    Lavy S, Stern S, Melamed E et al (1980) Effect of chronic atrial fibrillation on regional cerebral blood flow. Stroke 1:35–38CrossRefGoogle Scholar
  23. 23.
    Longo G, Cecchi F, Grossi A et al (1984) Coagulation and platelet function in hyper-trophic cardiomyopathy. Thromb Haemost 51:299PubMedGoogle Scholar
  24. 24.
    Yarom M, Lewis BS, Lijovetsky G et al (1982) Platelet studies in patients with hyper-trophic cardiomyopathy. Cardiovasc Res 16:324–330PubMedCrossRefGoogle Scholar
  25. 25.
    Fuster V, Ryden LE, Asinger RW et al (2003) ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. Circulation 104:2118–2150Google Scholar
  26. 26.
    McKenna WJ, Oakley CM, Krikler DM, Goodwin JF (1985) Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 53:412–416PubMedCrossRefGoogle Scholar
  27. 27.
    Cecchi F, Olivotto I, Montereggi A et al (1998) Prognostic value of nonsustained ventricular tachycardia and efficacy of amiodarone treatment in an unselected patient population with hypertrophic cardiomyopathy. Heart 79:331–336PubMedGoogle Scholar
  28. 28.
    Friedman PA, Dijkman B, Warman EN et al (2001) Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation 104:1023–1028PubMedCrossRefGoogle Scholar
  29. 29.
    Wyse DG, Waldo AL, DiMarco JP et al (2002) Atrial fibrillation follow-up investigation of rhythm management (AFFIRM) investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • F. Cecchi
    • 1
  • I. Olivotto
    • 1
  1. 1.Regional Referral Center for Myocardial DiseasesAzienda Ospedaliera CareggiFlorenceItaly

Personalised recommendations